Cytokinetics to Present at April Investor Conferences
April 01 2019 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to present a corporate update at the following investor
conferences:
- H.C. Wainwright Global Life Sciences
Conference on Monday, April 8, 2019 at 9:50 AM GMT
on at the Grosvenor House Hotel in London
- 18th Annual Needham Healthcare Conference on
Wednesday, April 10, 2019 at 8:40 AM EST at the Westin Grand
Central Hotel in New York
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics'
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
Phase 3 clinical trials program including GALACTIC-HF and
METEORIC-HF. Amgen holds an exclusive worldwide license to develop
and commercialize omecamtiv mecarbil with a sublicense held by
Servier for commercialization in Europe and certain other
countries. Cytokinetics is collaborating with Astellas Pharma Inc.
(Astellas) to develop reldesemtiv, a fast skeletal muscle troponin
activator (FSTA). Reldesemtiv has been granted orphan drug
designation by the FDA for the potential treatment of spinal
muscular atrophy. Reldesemtiv was the subject of a Phase 2 clinical
study in patients with spinal muscular atrophy which showed
increases in measures of endurance and stamina consistent with the
mechanism of action. Reldesemtiv is currently the subject of a
Phase 2 clinical trial in patients with amyotrophic lateral
sclerosis. Astellas holds an exclusive worldwide license to develop
and commercialize reldesemtiv. Licenses held by Amgen and Astellas
are subject to specified co-development and co-commercialization
rights of Cytokinetics. Cytokinetics is also developing CK-274, a
novel cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking StatementsThis
press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the
"Act"). Cytokinetics disclaims any intent or obligation
to update these forward-looking statements and claims the
protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its
partners' research and development activities of Cytokinetics’
product candidates. Such statements are based on management's
current expectations, but actual results may differ materially due
to various risks and uncertainties, including, but not limited to
the risks related to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Cytokinetics Diane Weiser Vice
President, Corporate Communications, Investor Relations(650)
624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024